CAMBRIDGE, Mass. ( TheStreet) -- Besides France's Sanofi-Aventis ( SNY), Genzyme's potential suitors might include GlaxoSmithKline ( GSK) and Johnson and Johnson ( JNJ), a report says. News of Sanofi's interest in Genzyme, the U.S. biotechnology company, became public Friday and Britain's GlaxoSmithKline and J&J are seen as the other most logical suitors for Genzyme, bankers and analysts said, according to the Wall Street Journal. Glaxo recently made a very casual approach to Genzyme, telling executives there to keep Glaxo company in mind if Genzyme thought about selling itself, a person familiar with the matter told the Journal. But the contact ended there and there hasn't been continuing dialogue after the casual expression of interest, these people said. Glaxo and and Johnson & Johnson declined to comment for the newspaper. Genzyme had $4.5 billion in sales last year. -- Written by Joseph Woelfel in New York. Get more stock ideas and investing advice on our sister site, Stockpickr.com.
Genzyme Corporation (Nasdaq:GENZ) hit a new 52-week high Wednesday as it changed hands at $76.10 compared with its previous 52-week high of $76.09. Genzyme is currently trading at $76.08 with 210,583 shares changing hands as of 9:41 a.m.